Collegium (Nasdaq: COLL) posts record 2025 revenue and EBITDA
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Collegium Pharmaceutical reported strong fourth-quarter and full-year 2025 results, led by its ADHD drug Jornay PM and its pain portfolio. Q4 2025 product revenues, net were $205.4 million, up 13% year-over-year, and adjusted EBITDA reached $127.3 million, up 18%.
For full-year 2025, product revenues, net grew to $780.6 million from $631.4 million, a 24% increase, while adjusted EBITDA rose to $460.5 million, up 15%. Jornay PM net revenue was $148.9 million, up 48%, and the pain portfolio delivered $631.7 million, up 6%.
GAAP net income for 2025 was $62.9 million (diluted EPS $1.73), down from $69.2 million in 2024, while non-GAAP adjusted net income increased to $289.3 million (adjusted EPS $7.42). The company generated $329.3 million in cash from operations and ended 2025 with $386.7 million in cash, cash equivalents and marketable securities. A new $980 million syndicated credit facility refinanced prior debt and is expected to lower interest costs. Collegium reaffirmed its 2026 guidance, including product revenues, net of $805–$825 million and adjusted EBITDA of $455–$475 million.
Positive
- Strong 2025 growth and profitability: Product revenues, net rose 24% to $780.6 million and adjusted EBITDA increased 15% to $460.5 million, driven by 48% Jornay PM revenue growth and 6% pain portfolio growth.
- Improved balance sheet and liquidity: The company generated $329.3 million in operating cash flow, ended 2025 with $386.7 million in cash, cash equivalents and marketable securities, and secured a $980 million syndicated credit facility expected to lower interest costs.
Negative
- GAAP earnings pressured despite growth: GAAP net income declined to $62.9 million in 2025 from $69.2 million in 2024, while GAAP operating expenses increased 37% and adjusted operating expenses rose 58%, reflecting higher costs alongside expansion.
Insights
Collegium delivered strong 2025 growth with rising cash generation.
Collegium posted 2025 product revenues, net of
Non-GAAP adjusted net income increased to
The new
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) (Zip Code) | ||||||||
Registrant’s telephone number, including area code: (781 ) 713-3699
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period and fiscal year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On February 26, 2026, Collegium Pharmaceutical, Inc. released an earnings presentation. The presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| EXHIBIT TABLE | |||||||||||
| Exhibit No. | Description | ||||||||||
99.1 | Press Release, dated February 26, 2026 | ||||||||||
99.2 | Earnings Presentation, dated February 26, 2026 | ||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Collegium Pharmaceutical, Inc. | ||||||||
| By: | /s/ Colleen Tupper | |||||||
| Colleen Tupper | ||||||||
| Executive Vice President and Chief Financial Officer | ||||||||
Dated: February 26, 2026
Exhibit 99.1
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year –
– Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year –
– Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year –
– Ended 2025 with Cash, Cash Equivalents, and Marketable Securities of $386.7 Million –
– Reaffirmed Full-Year 2026 Guidance –
– Conference Call Scheduled for Today at 8:00 a.m. ET –
STOUGHTON, Mass., February 26, 2026 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter and full year ended December 31, 2025, and provided a business update.
“In 2025, we delivered on our strategic priorities by driving significant growth for Jornay PM, maximizing the durability of our pain portfolio, and strategically deploying capital,” said Vikram Karnani, President and Chief Executive Officer. “In our first full year of owning Jornay PM, we grew full-year net revenue by 48% and reached a record number of prescribers in support of our differentiated medicine for the treatment of ADHD. Our investments to expand the sales force and sharpen our marketing approach are already fueling additional momentum. Importantly, these results, including solid performance across our pain portfolio, reflect more than a strong year of execution. They underscore the foundation we are building to drive sustained growth and deliver value for patients and shareholders. With a strengthened financial profile and a strong start to 2026, we are well positioned to build on this momentum and continue creating long-term value.”
“Net revenues and adjusted EBITDA reached record highs in 2025, growing 24% and 15%, respectively, driven by strong performance from both Jornay PM and our pain portfolio. We generated significant operating cash flows, improved our debt terms, and repurchased $25 million of shares,” said Colleen Tupper, Chief Financial Officer. “In 2026, we expect another year of significant growth for Jornay PM and durable performance from our pain portfolio. We remain committed to our capital deployment strategy, prioritizing business development opportunities, opportunistic share repurchases, and paying down debt, all of which are intended to create long-term value.”
ADHD Business Highlights
•Generated record Jornay PM net revenue in the quarter ended December 31, 2025 (the 2025 Quarter) and the year ended December 31, 2025 (FY 2025). Jornay PM net revenue was $45.9 million in the 2025 Quarter, up 57% year-over-year. Jornay PM net revenue was $148.9 million for FY 2025, up 48% compared to pro forma net revenue in 2024.
•Jornay PM prescriptions reached an all-time high in the 2025 Quarter, with over 200,000 prescriptions written, up 16% year-over-year, and over 760,000 prescriptions written in FY 2025, up 20% year-over-year.
•Jornay PM prescribers reached an all-time high in the 2025 Quarter, with 29,000 healthcare providers writing Jornay PM prescriptions, up 21% year-over-year.
•In 2025, presented at four scientific congresses and completed four real-world evidence studies supporting Jornay PM.
•In January, presented four posters at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference highlighting real-world Jornay PM data.
Pain Portfolio Highlights
•Grew net revenues from the pain portfolio to $159.6 million in the 2025 Quarter, up 5% year-over-year. Pain portfolio net revenues were a record $631.7 million for FY 2025, up 6% year-over-year.
•Generated Belbuca® net revenue of $59.1 million in the 2025 Quarter, up 7% year-over-year. Belbuca net revenue was $221.7 million for FY 2025, up 5% year-over-year.
•Generated Xtampza® ER net revenue of $48.6 million in the 2025 Quarter, down 6% year-over-year. Xtampza ER net revenue was $199.3 million for FY 2025, up 4% year-over-year.
•Generated Nucynta Franchise net revenue of $47.9 million, up 15% year-over-year. Nucynta Franchise net revenue was $196.3 million for FY 2025, up 11% year-over-year.
•In January, announced supply and quality agreements with Hikma Pharmaceuticals USA Inc. (Hikma), in connection with the authorized generic (AG) agreement Collegium previously announced in April 2024. Hikma will have the exclusive right to sell the Collegium-supplied authorized generics of Nucynta and Nucynta ER in the United States. Hikma recently launched an AG of Nucynta and is expected to launch Nucynta ER in Q1 2026. Collegium will receive a significant share of net profits of the AG products which would decline based on the number of third-party generic equivalents sold for each product, if any.
•In 2025, presented at three scientific congresses and completed three real-world evidence studies supporting the pain portfolio.
Corporate Updates
•In December, announced the successful closing of a $980 million syndicated credit facility, which was used in part to repay the remaining $581 million of principal representing the entire remaining balance of the Company’s previous $646 million term loan secured from funds managed by Pharmakon Advisors, LP. The new aggregate credit facility consists of a five-year $580 million senior secured term loan, $300 million delayed draw term loan, and $100 million revolving credit facility (collectively the Credit Facility). The reduced rate on the new Credit Facility is expected to result in meaningful annualized interest savings. The delayed draw term loan and revolving credit facility, both currently undrawn, are available to be used for general corporate purposes, including to partially fund potential future business development opportunities.
Upcoming Events
The Company will participate in the following upcoming investor conferences in the first half of 2026:
•Leerink Global Healthcare Conference – Miami, FL; March 9, 2026
•Jefferies Biotech on the Beach Summit – Miami, FL; March 10, 2026
•Citizens Life Sciences Conference – Miami, FL; March 10, 2026
•Barclays 28th Annual Global Healthcare Conference – Miami, FL; March 11, 2026
•25th Annual Needham Virtual Healthcare Conference – Virtual; April 15, 2026
Financial Guidance for 2026
The Company reaffirms its full-year 2026 guidance for Product Revenues, Net, Jornay PM Revenue, Net and Adjusted EBITDA:
| Product Revenues, Net | $805 to $825 million | |||||||||||||
| Jornay PM Revenue, Net | $190 to $200 million | |||||||||||||
| Adjusted EBITDA | $455 to $475 million | |||||||||||||
Financial Results for Quarter Ended December 31, 2025
•Product revenues, net were $205.4 million for the 2025 Quarter, compared to $181.9 million for the quarter ended December 31, 2024 (the 2024 Quarter), representing a 13% increase year-over-year.
•GAAP operating expenses were $67.6 million for the 2025 Quarter, compared to $60.2 million for the 2024 Quarter, representing a 12% increase year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were $57.5 million for the 2025 Quarter, compared to $51.1 million for the 2024 Quarter, representing a 13% increase year-over-year.
•GAAP net income for the 2025 Quarter was $17.0 million, with $0.54 GAAP earnings per share (basic) and $0.46 GAAP earnings per share (diluted), compared to GAAP net income for the 2024 Quarter of $12.5 million, with $0.39 GAAP earnings per share (basic) and $0.36 GAAP earnings per share (diluted). Non-GAAP adjusted net income for the 2025 Quarter was $80.3 million, with $2.04 adjusted earnings per share, compared to non-GAAP adjusted net income for the 2024 Quarter of $68.5 million, with $1.77 adjusted earnings per share.
•Adjusted EBITDA for the 2025 Quarter was $127.3 million, compared to $107.7 million for the 2024 Quarter, representing an 18% increase year-over-year.
•The Company generated $123.0 million in cash from operations in the 2025 Quarter.
Financial Results for Year Ended December 31, 2025
•Product revenues, net were $780.6 million for FY 2025, compared to $631.4 million for the year ended December 31, 2024 (FY 2024), representing a 24% increase year-over-year.
•GAAP operating expenses were $283.6 million for FY 2025, compared to $207.4 million for FY 2024, representing a 37% increase year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were $237.3 million for FY 2025, compared to $150.6 million for FY 2024, representing a 58% increase year-over-year.
•GAAP net income for FY 2025 was $62.9 million, with $1.98 GAAP earnings per share (basic) and $1.73 GAAP earnings per share (diluted), compared to GAAP net income for FY 2024 of $69.2 million, with $2.14 GAAP earnings per share (basic) and $1.86 GAAP earnings per share (diluted). Non-GAAP adjusted net income for FY 2025 was $289.3 million, with $7.42 adjusted earnings per share, compared to non-GAAP adjusted net income for FY 2024 of $254.8 million, with $6.45 adjusted earnings per share.
•Adjusted EBITDA for FY 2025 was $460.5 million, compared to $401.2 million for FY 2024, representing a 15% increase year-over-year.
•The Company generated $329.3 million in cash from operations in FY 2025, and exited the year with cash, cash equivalents and marketable securities of $386.7 million as of December 31, 2025.
Conference Call Information
The Company will host a conference call and live audio webcast on Thursday, February 26, 2026, at 8:00 a.m. ET. To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Fourth Quarter and Full-Year 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Non-GAAP Financial Measures
To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management.
We may discuss the following financial measures that are not calculated in accordance with GAAP in our quarterly and annual reports, earnings press releases, and conference calls.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as:
•adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
•adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes;
•adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;
•we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
•we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business;
•we exclude litigation settlements and contingencies that are subject to recovery from adjusted EBITDA, as well as any applicable income items, credit adjustments, or recoveries due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred;
•we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, legal defense expenses for specific acquired claims that relate to acts that occurred prior to our acquisition, and miscellaneous other acquisition related expenses incurred;
•we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business;
•we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis;we exclude executive transition expenses from adjusted EBITDA as the amount and/or frequency of these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; and
•we exclude other expenses, from time to time, that are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis.
Adjusted Operating Expenses
Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.
Adjusted Net Income and Adjusted Earnings Per Share
Adjusted net income is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude significant income and expense items that are non-cash or not indicative of ongoing operations, including consideration of the tax effect of the adjustments. Adjusted earnings per share is a non-GAAP financial measure that represents adjusted net income per share. Adjusted weighted-average shares - diluted is calculated in accordance with the treasury stock, if-converted, or contingently issuable accounting methods, depending on the nature of the security.
Reconciliations of adjusted EBITDA, adjusted operating expenses, adjusted net income, and adjusted earnings per share to the most directly comparable GAAP financial measures are included in this press release.
The Company has not provided a reconciliation of its full-year 2025 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements. These items are uncertain and depend on various factors that are outside of the Company’s control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA or adjusted operating expenses would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our 2026 financial guidance, including projected product revenues, adjusted operating expenses and adjusted EBITDA, statements related to the projected launch of the authorized generic versions of Nucynta and Nucynta ER and anticipated shared net profits following the launch of such authorized generic versions, statements related to current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenues, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com
Collegium Pharmaceutical, Inc.
Unaudited Selected Consolidated Balance Sheet Information
(in thousands)
| December 31, | December 31, | |||||||||||||||||||
| 2025 | 2024 | |||||||||||||||||||
| Cash and cash equivalents | $ | 231,252 | $ | 70,565 | ||||||||||||||||
| Marketable securities | 155,427 | 92,198 | ||||||||||||||||||
| Accounts receivable, net | 211,328 | 228,540 | ||||||||||||||||||
| Inventory | 40,912 | 35,560 | ||||||||||||||||||
| Prepaid expenses and other current assets | 32,642 | 30,394 | ||||||||||||||||||
| Property and equipment, net | 12,013 | 14,329 | ||||||||||||||||||
| Operating lease right-of-use assets | 4,187 | 5,822 | ||||||||||||||||||
| Intangible assets, net | 669,510 | 891,402 | ||||||||||||||||||
| Restricted cash | 20,906 | 26,047 | ||||||||||||||||||
| Deferred tax assets | 112,539 | 98,033 | ||||||||||||||||||
| Other noncurrent assets | 20,193 | 8,368 | ||||||||||||||||||
| Goodwill | 145,925 | 162,333 | ||||||||||||||||||
| Total assets | $ | 1,656,834 | $ | 1,663,591 | ||||||||||||||||
| Accounts payable and accrued liabilities | 73,123 | 76,058 | ||||||||||||||||||
| Accrued rebates, returns and discounts | 318,266 | 338,642 | ||||||||||||||||||
| Business combination consideration payable | 17,565 | 28,956 | ||||||||||||||||||
| Term notes payable | 571,112 | 615,316 | ||||||||||||||||||
| Convertible senior notes | 238,213 | 237,172 | ||||||||||||||||||
| Operating lease liabilities | 5,539 | 6,810 | ||||||||||||||||||
| Deferred royalty obligation | 121,563 | 120,613 | ||||||||||||||||||
| Deferred revenue | 9,778 | 10,000 | ||||||||||||||||||
| Contingent consideration | — | 1,182 | ||||||||||||||||||
| Shareholders’ equity | 301,675 | 228,842 | ||||||||||||||||||
| Total liabilities and shareholders’ equity | $ | 1,656,834 | $ | 1,663,591 | ||||||||||||||||
Collegium Pharmaceutical, Inc.
Unaudited Condensed Statements of Operations
(in thousands, except share and per share amounts)
| Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||||||||
| Product revenues, net | $ | 205,449 | $ | 181,949 | $ | 780,567 | $ | 631,449 | ||||||||||||||||||||||||||||||
| Cost of product revenues | ||||||||||||||||||||||||||||||||||||||
| Cost of product revenues (excluding intangible asset amortization) | 21,598 | 28,190 | 95,418 | 88,801 | ||||||||||||||||||||||||||||||||||
| Intangible asset amortization | 55,473 | 55,471 | 221,892 | 165,304 | ||||||||||||||||||||||||||||||||||
| Total cost of product revenues | 77,071 | 83,661 | 317,310 | 254,105 | ||||||||||||||||||||||||||||||||||
| Gross profit | 128,378 | 98,288 | 463,257 | 377,344 | ||||||||||||||||||||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative | 67,640 | 63,091 | 284,803 | 210,363 | ||||||||||||||||||||||||||||||||||
| Gain on fair value remeasurement of contingent consideration | (19) | (2,914) | (1,182) | (2,914) | ||||||||||||||||||||||||||||||||||
| Total operating expenses | 67,621 | 60,177 | 283,621 | 207,449 | ||||||||||||||||||||||||||||||||||
| Income from operations | 60,757 | 38,111 | 179,636 | 169,895 | ||||||||||||||||||||||||||||||||||
| Interest expense | (19,292) | (22,654) | (82,312) | (73,974) | ||||||||||||||||||||||||||||||||||
| Interest income | 3,565 | 1,812 | 11,289 | 13,976 | ||||||||||||||||||||||||||||||||||
| Loss on extinguishment of debt | (15,994) | — | (15,994) | (11,329) | ||||||||||||||||||||||||||||||||||
| Income before income taxes | 29,036 | 17,269 | 92,619 | 98,568 | ||||||||||||||||||||||||||||||||||
| Provision for income taxes | 12,073 | 4,733 | 29,749 | 29,378 | ||||||||||||||||||||||||||||||||||
| Net income | $ | 16,963 | $ | 12,536 | $ | 62,870 | $ | 69,190 | ||||||||||||||||||||||||||||||
| Earnings per share — basic | $ | 0.54 | $ | 0.39 | $ | 1.98 | $ | 2.14 | ||||||||||||||||||||||||||||||
| Weighted-average shares — basic | 31,652,987 | 32,078,621 | 31,706,429 | 32,273,850 | ||||||||||||||||||||||||||||||||||
| Earnings per share — diluted | $ | 0.46 | $ | 0.36 | $ | 1.73 | $ | 1.86 | ||||||||||||||||||||||||||||||
| Weighted-average shares — diluted | 40,076,457 | 40,109,649 | 39,701,693 | 40,424,180 | ||||||||||||||||||||||||||||||||||
Collegium Pharmaceutical, Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA
(in thousands)
(unaudited)
| Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||||||||
| GAAP net income | $ | 16,963 | $ | 12,536 | $ | 62,870 | $ | 69,190 | ||||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||||||
| Interest expense | 19,292 | 22,654 | 82,312 | 73,974 | ||||||||||||||||||||||||||||||||||
| Interest income | (3,565) | (1,812) | (11,289) | (13,976) | ||||||||||||||||||||||||||||||||||
| Loss on extinguishment of debt | 15,994 | — | 15,994 | 11,329 | ||||||||||||||||||||||||||||||||||
| Provision for income taxes | 12,073 | 4,733 | 29,749 | 29,378 | ||||||||||||||||||||||||||||||||||
| Depreciation | 923 | 1,041 | 4,182 | 3,856 | ||||||||||||||||||||||||||||||||||
| Amortization | 55,473 | 55,471 | 221,892 | 165,304 | ||||||||||||||||||||||||||||||||||
| Stock-based compensation | 9,753 | 7,596 | 41,906 | 32,400 | ||||||||||||||||||||||||||||||||||
| Litigation settlements and contingencies | — | — | 3,058 | — | ||||||||||||||||||||||||||||||||||
| Recognition of step-up basis in inventory | — | 3,968 | 5,431 | 5,269 | ||||||||||||||||||||||||||||||||||
| Executive transition expense | — | — | 1,397 | 3,051 | ||||||||||||||||||||||||||||||||||
| Acquisition related expenses | 399 | 4,443 | 4,175 | 24,329 | ||||||||||||||||||||||||||||||||||
| Gain on fair value remeasurement of contingent consideration | (19) | (2,914) | (1,182) | (2,914) | ||||||||||||||||||||||||||||||||||
| Total adjustments | $ | 110,323 | $ | 95,180 | $ | 397,625 | $ | 332,000 | ||||||||||||||||||||||||||||||
| Adjusted EBITDA | $ | 127,286 | $ | 107,716 | $ | 460,495 | $ | 401,190 | ||||||||||||||||||||||||||||||
Collegium Pharmaceutical, Inc.
Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
(in thousands)
(unaudited)
| Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||||||||
| GAAP operating expenses | $ | 67,621 | $ | 60,177 | $ | 283,621 | $ | 207,449 | ||||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | 9,753 | 7,596 | 41,906 | 32,400 | ||||||||||||||||||||||||||||||||||
| Executive transition expense | — | — | 1,397 | 3,051 | ||||||||||||||||||||||||||||||||||
| Acquisition related expenses | 399 | 4,443 | 4,175 | 24,329 | ||||||||||||||||||||||||||||||||||
| Gain on fair value remeasurement of contingent consideration | (19) | (2,914) | (1,182) | (2,914) | ||||||||||||||||||||||||||||||||||
| Total adjustments | $ | 10,133 | $ | 9,125 | $ | 46,296 | $ | 56,866 | ||||||||||||||||||||||||||||||
| Adjusted operating expenses | $ | 57,488 | $ | 51,052 | $ | 237,325 | $ | 150,583 | ||||||||||||||||||||||||||||||
Collegium Pharmaceutical, Inc.
Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share
(in thousands, except share and per share amounts)
(unaudited)
| Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||||||||
| GAAP net income | $ | 16,963 | $ | 12,536 | $ | 62,870 | $ | 69,190 | ||||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||||||
| Non-cash interest expense | 1,276 | 4,664 | 5,341 | 9,729 | ||||||||||||||||||||||||||||||||||
| Loss on extinguishment of debt | 15,994 | — | 15,994 | 11,329 | ||||||||||||||||||||||||||||||||||
| Amortization | 55,473 | 55,471 | 221,892 | 165,304 | ||||||||||||||||||||||||||||||||||
| Stock-based compensation | 9,753 | 7,596 | 41,906 | 32,400 | ||||||||||||||||||||||||||||||||||
| Litigation settlements and contingencies | — | — | 3,058 | — | ||||||||||||||||||||||||||||||||||
| Recognition of step-up basis in inventory | — | 3,968 | 5,431 | 5,269 | ||||||||||||||||||||||||||||||||||
| Executive transition expense | — | — | 1,397 | 3,051 | ||||||||||||||||||||||||||||||||||
| Acquisition related expenses | 399 | 4,443 | 4,175 | 24,329 | ||||||||||||||||||||||||||||||||||
| Gain on fair value remeasurement of contingent consideration | (19) | (2,914) | (1,182) | (2,914) | ||||||||||||||||||||||||||||||||||
Income tax effect of above adjustments (1) | (19,538) | (17,245) | (71,599) | (62,880) | ||||||||||||||||||||||||||||||||||
| Total adjustments | $ | 63,338 | $ | 55,983 | $ | 226,413 | $ | 185,617 | ||||||||||||||||||||||||||||||
| Non-GAAP adjusted net income | $ | 80,301 | $ | 68,519 | $ | 289,283 | $ | 254,807 | ||||||||||||||||||||||||||||||
Adjusted weighted-average shares — diluted (2) | 40,076,457 | 40,109,649 | 39,701,693 | 40,424,180 | ||||||||||||||||||||||||||||||||||
Adjusted earnings per share (2) | $ | 2.04 | $ | 1.77 | $ | 7.42 | $ | 6.45 | ||||||||||||||||||||||||||||||
(1)The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended December 31, 2025 and 2024 were 25.5% and 25.3%, respectively; and the blended federal and state statutory rate for the years ended December 31, 2025 and 2024 were 24.8% and 26.5%, respectively. As such, the non-GAAP effective tax rates for the three months ended December 31, 2025 and 2024 were 23.6% and 23.5%, respectively; and the non-GAAP effective tax rates for the years ended December 31, 2025 and 2024 were 24.0% and 25.3%, respectively.
(2)Adjusted weighted-average shares - diluted were calculated using the “if-converted” method for our convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense is added-back to non-GAAP adjusted net income. For the three and twelve months ended December 31, 2025 and 2024, adjusted weighted-average shares – diluted includes 6,606,305 shares attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive.
Q4 and FY2025 Earnings Report February 26, 2026 | Nasdaq: COLL Healthier people. Stronger communities.
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this presentation include, among others, statements related to our full-year 2026 financial guidance, including projected product revenues, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenues, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this presentation speak only as of the date of this presentation. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this presentation. Non-GAAP Financial Measures To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily Adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management. In this presentation, we discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis. Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as: • adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; • adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs; • adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes; • adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments; • we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position; • we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; • we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business; • we exclude litigation settlements and contingencies that are subject to recovery from adjusted EBITDA, as well as any applicable income items, credit adjustments, or recoveries due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred; • we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, legal defense expenses for specific acquired claims that relate to acts that occurred prior to our acquisition, and miscellaneous other acquisition related expenses incurred; • we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business; • we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; • we exclude executive transition expenses from adjusted EBITDA as the amount and/or frequency of these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; and • we exclude other expenses, from time to time, that are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis. Adjusted Operating Expenses Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted Net Income and Adjusted Earnings Per Share Adjusted net income is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude significant income and expense items that are non-cash or not indicative of ongoing operations, including consideration of the tax effect of the adjustments. Adjusted earnings per share is a non-GAAP financial measure that represents adjusted net income per share. Adjusted weighted-average shares - diluted is calculated in accordance with the treasury stock, if-converted, or contingently issuable accounting methods, depending on the nature of the security. Reconciliations of adjusted EBITDA and adjusted operating expenses to the most directly comparable GAAP financial measures are included in this presentation. The Company has not provided a reconciliation of its full-year 2026 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S- K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements. These items are uncertain and depend on various factors that are outside of the Company’s control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA or adjusted operating expenses would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.
Business Update Vikram Karnani President & Chief Executive Officer
4 Building a Leading, Diversified Biopharmaceutical Company 1. This financial data was provided by Collegium in its Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. Healthier people. Stronger communities. 2025 RECAP $461M 2025 Adjusted EBITDA1,2 $781M 2025 Product Sales1 2 Current focus areas: ADHD & Pain BY THE NUMBERS Drove significant growth for Jornay PM Maximized the durability of the Pain Portfolio Strategically deployed capital Demonstrated our commitment to ‘Doing Good as We Do Well’
Recent Business Highlights1 1. Unless otherwise noted, this financial data was provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. 3. Net debt/adjusted EBITDA is calculated based on financial data provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. Accelerated Commercial Momentum +48% YoY growth in 2025 net revenue +6% YoY growth in 2025 net revenues Pain Portfolio Strategically Deployed Capital and Strengthened Balance Sheet Generated $329M in cash flows from operations in 2025; $387M in cash, cash equivalents, and marketable securities at end of 2025, up $224M from end of 2024 <1x net debt to adjusted EBITDA at end of 20252,3 $980M syndicated credit facility that improves debt terms and provides flexibility for potential business development opportunities $25M in share repurchases conducted in 2025 5 Achieved Top-and Bottom-line Growth Product Revenues, Net $631M 2024 $781M 2025 $401M 2024 $461M 2025 +24% +15% Adjusted EBITDA2
Drive further growth for Jornay PM 6 Strategic Priorities to Drive Value Creation Grows revenue Extends longevity Increases profitability Generates robust cash flows Diversifies portfolio Strengthens balance sheet VALUE CREATION 2026 Strategic Priorities Maximize the durability of the Pain Portfolio Strategically deploy capital • Business development • Debt repayment • Share repurchases
Collegium’s Vision for the Next Phase of Growth 7 Time O pp or tu ni ty FUTURE FURTHER EXPANSION Product diversification and capital deployment NEUROPSYCHIATRY and PEDIATRICS PAIN PORTFOLIO FUTURE
Commercial Update Scott Dreyer Executive Vice President & Chief Commercial Officer
Product Differentiation and Strong Brand Fundamentals Drive Utilization1 91. ATU (Awareness, Trial, & Usage) Market Research Study, completed Q2 2025. Strong Intent to Increase PrescribingJornay PM Considered Highly Differentiated #1 highest rated branded ADHD medicine in terms of product differentiation >60% of surveyed HCPs plan to increase prescribing (highest among all other branded ADHD medicines) >70% of patients/caregivers who request Jornay PM from their physician, receive it
Q4'24 Q4'25Q4'24 Q4'25 Fastest Growing Stimulant for Treatment of ADHD 10 STRONG AND GROWING PRESCRIBER BASE2 GROWTH IN QUARTERLY PRESCRIPTIONS1 MARKET SHARE IN BRANDED LONG-ACTING METHYLPHENIDATE MARKET1 Q4'24 Q4'25 +16% +21% GROWTH IN AVERAGE WEEKLY PRESCRIPTIONS DURING “BACK-TO- SCHOOL” SEASON1 July '25 December '25 +20% 177K 206K 24K 29K 19% 26% 14K 17K +6.5 Percentage Points 1. IQVIA NPA through December 2025. 2. IQVIA Xponent through December 2025; approximate quarterly prescriber counts.
Investing in Jornay PM to Drive Additional Momentum 11 1. Increase awareness and adoption with expanded set of prescribers 2. Raise caregiver and patient awareness to drive HCP request 3. Increase depth of prescribing with targeted physicians 4. Maintain broad patient access $149M $190 – 200M 2025 2026E JORNAY PM 2026 REVENUE EXPECTATIONS1 COMMERCIAL PRIORITIES FOCUSED ON GROWTH +31% 1. This financial data is calculated based on data provided by Collegium in its press release on Form 8-K filed with the SEC on February 26, 2026. The estimated year-over-year change represents the mid-point of the 2026 financial guidance range compared to 2025 financial results.
12 Well Positioned to Maximize Durability of Responsible Pain Management Portfolio 1. This financial data was provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. ATU (Awareness, Trial, & Usage) Market Research Study, fielded Q4 2022. #1 highest rated branded ER opioid in terms of product differentiation and favorability 74% of surveyed target HCPs plan to increase prescribing STRONG BRAND FUNDAMENTALS2 #1 highest rated ER oxycodone in terms of product differentiation and favorability 48% of surveyed target HCPs plan to increase prescribing SUCCESSFUL COMMERCIAL EXECUTION OF STRATEGY1 $48.6M Q4’25 revenue $59.1M Q4’25 revenue
Financial Highlights Colleen Tupper Executive Vice President & Chief Financial Officer
Q4 and FY2025 Financial Highlights1 14 1. This financial data was provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. $631M $781M 2024 2025 Record Product Revenues, Net $182M $205M Q4'24 Q4'25 +13% +24% Adjusted Operating Expenses2 $151M $237M 2024 2025 $51M $58M Q4'24 Q4'25 +13% +58% Record Adjusted EBITDA2 $401M $461M 2024 2025 $108M $127M Q4'24 Q4'25 +18% +15% QUARTERLY FULL-YEAR
2026 Guidance Range2 YoY Change3 Product Revenues, Net $805 – 825M +4% Jornay PM Revenue, Net $190 – 200M +31% Adjusted EBITDA1 $455 – 475M +1% 2026 Financial Guidance 15 1. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. 2. This financial data was provided by Collegium in its press release on Form 8-K filed with the SEC on February 26, 2026. 3. This financial data is calculated based on data provided by Collegium in its press release on Form 8-K filed with the SEC on February 26, 2026. The estimated year-over-year change represents the mid-point of 2026 financial guidance ranges compared to 2025 financial results.
Disciplined Capital Deployment 16 1. Adjusted EBITDA is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. Net debt/adjusted EBITDA is calculated based on financial data provided by Collegium in its press release on Form 8-K and Annual Report on Form 10-K filed with the SEC on February 26, 2026. 2. This financial data was provided by Collegium in its Annual Reports on Form 10-K filed with the SEC on February 22, 2024, February 27, 2025, and February 26, 2026. EXPAND PORTFOLIO THROUGH BUSINESS DEVELOPMENT • Acquisition of Ironshore added lead growth driver, Jornay PM, new sales force in neuropsychiatry & pediatrics, and new platform for growth in ADHD • Further expand and diversify portfolio through business development OPPORTUNISTICALLY LEVERAGE SHARE REPURCHASE PROGRAM2 • $25M in share repurchases conducted in 2025 • Returned $222M of value to shareholders since 2021 • $150M share repurchase program authorized by Board through December 2026 DISCIPLINED DEBT MANAGEMENT • <1x net debt to adjusted EBITDA at end of 20251 • Successfully closed $980M syndicated credit facility, improving interest rate and debt terms, providing flexibility for potential business development opportunities
Disciplined Business Development Approach TARGET THERAPEUTIC AREAS • Neuropsychiatry and pediatrics • Other specialty conditions (case-by-case) • Rare diseases (case-by-case) Guiding Framework for Near-term BD Efforts ADDITIONAL FEATURES While maintaining robust cash generation and financial strength 17 • Commercial or near-commercial • Cost efficient sales and marketing requirements • LOE into 2030’s and beyond
Closing Remarks Vikram Karnani President & Chief Executive Officer
Creating Value for Shareholders 19 19 2026 STRATEGIC PRIORITIES VALUE CREATION 1. Drive significant growth for Jornay PM 2. Maximize the durability of the Pain Portfolio 3. Strategically deploy capital • Business Development • Debt repayment • Share repurchases Grow Revenues Extend longevity Increase profitability Generate robust cash flows Diversify portfolio Strengthen balance sheet
20 Healthier people. Stronger communities. Building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.
Non-GAAP Reconciliations
Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands, unaudited) 22 GAAP net income $ 16,963 $ 12,536 $ 62,870 $ 69,190 Adjustments: Interest expense 19,292 22,654 82,312 73,974 Interest income (3,565) (1,812) (11,289) (13,976) Loss on extinguishment of debt 15,994 — 15,994 11,329 Provision for income taxes 12,073 4,733 29,749 29,378 Depreciation 923 1,041 4,182 3,856 Amortization 55,473 55,471 221,892 165,304 Stock-based compensation 9,753 7,596 41,906 32,400 Litigation settlements and contingencies — — 3,058 — Recognition of step-up basis in inventory — 3,968 5,431 5,269 Executive transition expense — — 1,397 3,051 Acquisition related expenses 399 4,443 4,175 24,329 Gain on fair value remeasurement of contingent consideration (19) (2,914) (1,182) (2,914) Total adjustments $ 110,323 $ 95,180 $ 397,625 $ 332,000 Adjusted EBITDA $ 127,286 $ 107,716 $ 460,495 $ 401,190 Three Months Ended December 31, 2025 Years Ended December 31, 2025 20242024
Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands, unaudited) 23 GAAP operating expenses $ 67,621 $ 60,177 $ 283,621 $ 207,449 Adjustments: Stock-based compensation 9,753 7,596 41,906 32,400 Executive transition expense — — 1,397 3,051 Acquisition related expenses 399 4,443 4,175 24,329 Gain on fair value remeasurement of contingent consideration (19) (2,914) (1,182) (2,914) Total adjustments $ 10,133 $ 9,125 $ 46,296 $ 56,866 Adjusted operating expenses $ 57,488 $ 51,052 $ 237,325 $ 150,583 Three Months Ended December 31, 2025 Years Ended December 31, 20242025 2024
Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts, unaudited) 24 1. The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended December 31, 2025 and 2024 were 25.5% and 25.3%, respectively; and the blended federal and state statutory rate for the years ended December 31, 2025 and 2024 were 24.8% and 26.5%, respectively. As such, the non-GAAP effective tax rates for the three months ended December 31, 2025 and 2024 were 23.6% and 23.5%, respectively; and the non-GAAP effective tax rates for the years ended December 31, 2025 and 2024 were 24.0% and 25.3%, respectively. 2. Adjusted weighted-average shares - diluted were calculated using the “if-converted” method for our convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense is added-back to non-GAAP adjusted net income. For the three and twelve months ended December 31, 2025 and 2024, adjusted weighted-average shares – diluted includes 6,606,305 shares attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive. GAAP net income $ 16,963 $ 12,536 $ 62,870 $ 69,190 Adjustments: Non-cash interest expense 1,276 4,664 5,341 9,729 Loss on extinguishment of debt 15,994 — 15,994 11,329 Amortization 55,473 55,471 221,892 165,304 Stock-based compensation 9,753 7,596 41,906 32,400 Litigation settlements and contingencies — — 3,058 — Recognition of step-up basis in inventory — 3,968 5,431 5,269 Executive transition expense — — 1,397 3,051 Acquisition related expenses 399 4,443 4,175 24,329 Gain on fair value remeasurement of contingent consideration (19) (2,914) (1,182) (2,914) Income tax effect of above adjustments (1) (19,538) (17,245) (71,599) (62,880) Total adjustments $ 63,338 $ 55,983 $ 226,413 $ 185,617 Non-GAAP adjusted net income $ 80,301 $ 68,519 $ 289,283 $ 254,807 Adjusted weighted-average shares — diluted (1) 40,076,457 40,109,649 39,701,693 40,424,180 Adjusted earnings per share (2) $ 2.04 $ 1.77 $ 7.42 $ 6.45 Three Months Ended December 31, 2025 Years Ended December 31, 2025 20242024
FAQ
How did Collegium Pharmaceutical (COLL) perform financially in 2025?
Collegium delivered strong 2025 growth, with product revenues, net rising to $780.6 million, up 24% year-over-year. Adjusted EBITDA increased to $460.5 million, up 15%, and non-GAAP adjusted net income reached $289.3 million, highlighting robust profitability alongside top-line expansion.
What were Collegium Pharmaceutical’s Q4 2025 results?
In Q4 2025, Collegium reported product revenues, net of $205.4 million, a 13% year-over-year increase. Adjusted EBITDA was $127.3 million, up 18%, while GAAP net income was $17.0 million. Non-GAAP adjusted net income for the quarter totaled $80.3 million, with adjusted EPS of $2.04.
How fast did Jornay PM revenue grow for Collegium in 2025?
Jornay PM was a key growth driver, generating $148.9 million in net revenue for 2025, up 48% year-over-year. Q4 2025 Jornay PM net revenue was $45.9 million, a 57% increase, supported by record prescriptions and prescriber counts in the ADHD market.
How did Collegium’s pain portfolio perform in 2025?
Collegium’s pain portfolio produced record 2025 net revenues of $631.7 million, up 6% year-over-year. Within this, Belbuca generated $221.7 million, Xtampza ER $199.3 million, and the Nucynta Franchise $196.3 million, reflecting resilient demand for its responsible pain management products.
What is Collegium Pharmaceutical’s 2026 financial guidance?
For 2026, Collegium reaffirmed guidance for product revenues, net of $805–$825 million and Jornay PM revenue, net of $190–$200 million. Adjusted EBITDA is projected between $455–$475 million, indicating continued revenue growth with more modest incremental EBITDA expansion versus 2025.
How strong is Collegium’s balance sheet and cash position after 2025?
Collegium exited 2025 with $386.7 million in cash, cash equivalents and marketable securities and generated $329.3 million in operating cash flow. A new $980 million syndicated credit facility refinanced prior term debt, improving interest terms and supporting future business development flexibility.
How do Collegium’s GAAP and non-GAAP earnings compare for 2025?
In 2025, GAAP net income was $62.9 million (diluted EPS $1.73), down from $69.2 million in 2024. However, non-GAAP adjusted net income increased to $289.3 million with adjusted EPS of $7.42, excluding amortization, stock-based compensation, acquisition-related costs and other non-recurring items.
Filing Exhibits & Attachments
5 documents
Collegium Pharmaceutical Inc
NASDAQ:COLL
COLL Rankings
COLL Latest News
COLL Latest SEC Filings
COLL Stock Data
1.43B
30.90M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
STOUGHTON